News | Breast Density | February 10, 2021

Screening strategy based on baseline breast density at age 40 may be effective and cost-effective for reducing breast cancer mortality

Screening strategy based on baseline breast density at age 40 may be effective and cost-effective for reducing breast cancer mortality

Getty Images


February 10, 2021 — A mammography screening strategy based on a baseline breast density measure at age 40 may be the most effective and cost effective way to reduce breast cancer mortality. Current breast cancer screening guidelines recommend that mammography begin at age 50 for women at average risk. Findings from a microsimulation modeling study are published in Annals of Internal Medicine.

High breast density not only has a masking effect on mammogram reading, it also increases the risk of breast cancer. The Breast Density Notification Act requires providers to inform women who have a mammogram whether they have dense breasts. However, most women do not know their breast density classification until after their first mammogram at age 50.

Researchers from the University of Texas MD Anderson Cancer Center and Fred Hutch Cancer Center used a microsimulation model to compare the health outcomes and cost-effectiveness of 7 breast cancer screening strategies: no screening, biennial screening between age 50-75, triennial screening between 50-75, and four density-stratified strategies (two with baseline mammogram at age 40, and the other two at age 50). All density-stratified strategies assigned annual screening to women with dense breasts, and biennial or triennial starting at age 50 for women without dense breasts.

The model suggests that the strategy with a baseline breast density assessment at age 40, followed by annual screening between age 40 and 75 for women with dense breasts and biennial screening between 50 and 75 for women without dense breasts had the greatest reduction in breast cancer mortality, but was also associated with a larger number of mammograms lifetime and higher rates of false positives and overdiagnosis. A cost-effectiveness analysis that considered the benefits and harms showed that when compared to non-density-stratified biennial screening age 50 - 75, the above density-stratified strategy yielded an incremental cost-effectiveness ratio of about $36,000 per quality-adjusted life year (QALY), which is considered cost-effective.

The authors of an accompany editorial from the University of California, San Francisco argue that breast density is an important risk factor to include in risk-based screening strategies because it is both a strong and prevalent risk factor accounting for a large proportion of breast cancers. However, it should be combined with age and other risk factors when developing risk-based screening strategies that optimize benefits and minimize harms. The editorialists believe that until a more robust risk-based strategy is identified, data supports screening biennially from ages 50 to 74 years.

For more information: www.acponline.org


Related Content

News | Women's Health

March 4, 2026 — QT Imaging Holdings recently announced that Mary W. Yamashita, MD will serve as medical advisor to the ...

Time March 06, 2026
arrow
News | Radiation Oncology

March 4, 2026 — Lunit has announced that 21 studies featuring its AI solutions will be presented at the European ...

Time March 05, 2026
arrow
News | Artificial Intelligence

March 2, 2026 — RadNet, Inc. has acquired Gleamer SAS, a radiology AI company based in Paris, France. Gleamer will be ...

Time March 03, 2026
arrow
News | Women's Health

Feb.23, 2026 — The first clinical patient received a Clairity Breast cancer risk score, marking a historic milestone in ...

Time February 23, 2026
arrow
News | Breast Biopsy Systems

Feb. 18, 2026 — Mammotome, a Danaher company, has introduced the Mammotome Prima MR Dual Vacuum-Assisted Breast Biopsy ...

Time February 18, 2026
arrow
News | Breast Imaging

Feb. 16, 2026 — Rising demand for breast cancer screening and diagnostics is outpacing the supply of available breast ...

Time February 17, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

Feb. 5, 2026 — Eyas Medical Imaging, Inc. has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its ...

Time February 06, 2026
arrow
News | Ultrasound Women's Health

Feb. 5, 2026 — BrightHeart, a global provider of AI-driven prenatal ultrasound, has announced the availability of its B ...

Time February 05, 2026
arrow
News | Radiation Therapy

Feb. 4, 2026 — On World Cancer Day (02.04.26), the American Society for Radiation Oncology (ASTRO) and the European ...

Time February 04, 2026
arrow
News | Radiology Imaging

Feb. 4, 2026 — The Royal College of Radiologists (RCR) has issued its initial reaction to the British government's ...

Time February 04, 2026
arrow
Subscribe Now